This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

This early-phase trial tests a new drug called ZM008, both on its own and combined with pembrolizumab (an immunotherapy), in patients with advanced cancers that have stopped responding to standard treatments. The study aims to find the safest and most effective dose. **You may be eligible if...** - You are 18 or older with an advanced solid tumor including lung, breast (triple negative), head and neck, prostate, colorectal, pancreatic, bile duct, ovarian, bladder cancer, or large B-cell lymphoma - Your cancer has progressed on all standard treatments or you cannot tolerate them - You are in reasonably good health and able to carry out daily activities - Your cancer has measurable lesions on imaging **You may NOT be eligible if...** - You have untreated brain metastases or serious active infections - Your blood counts, kidney, or liver function are significantly impaired - You have had certain immunotherapy-related complications in the past Talk to your doctor to see if this trial is right for you.